ID   ABCCB_HUMAN             Reviewed;        1382 AA.
AC   Q96J66; Q8TDJ0; Q96JA6; Q9BX80;
DT   07-MAR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 132.
DE   RecName: Full=ATP-binding cassette sub-family C member 11;
DE   AltName: Full=Multidrug resistance-associated protein 8;
GN   Name=ABCC11; Synonyms=MRP8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=11483364; DOI=10.1016/S0378-1119(01)00572-8;
RA   Tammur J., Prades C., Arnould I., Rzhetsky A., Hutchinson A.,
RA   Adachi M., Schuetz J.D., Swoboda K.J., Ptacek L.J., Rosier M.,
RA   Dean M., Allikmets R.;
RT   "Two new genes from the human ATP-binding cassette transporter
RT   superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome
RT   16q12.";
RL   Gene 273:89-96(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Liver;
RX   PubMed=11688999; DOI=10.1006/bbrc.2001.5865;
RA   Yabuuchi H., Shimizu H., Takayanagi S., Ishikawa T.;
RT   "Multiple splicing variants of two new human ATP-binding cassette
RT   transporters, ABCC11 and ABCC12.";
RL   Biochem. Biophys. Res. Commun. 288:933-939(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANTS GLU-317 AND ARG-1344.
RC   TISSUE=Mammary gland;
RX   PubMed=11591886;
RA   Bera T.K., Lee S., Salvatore G., Lee B.K., Pastan I.H.;
RT   "MRP8, a new member of ABC transporter superfamily, identified by EST
RT   database mining and gene prediction program, is highly expressed in
RT   breast cancer.";
RL   Mol. Med. 7:509-516(2001).
RN   [4]
RP   FUNCTION IN CYCLIC NUCLEOTIDE EFFLUX.
RX   PubMed=12764137; DOI=10.1074/jbc.M304059200;
RA   Guo Y., Kotova E., Chen Z.S., Lee K., Hopper-Borge E., Belinsky M.G.,
RA   Kruh G.D.;
RT   "MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide
RT   efflux pump and a resistance factor for fluoropyrimidines 2',3'-
RT   dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine.";
RL   J. Biol. Chem. 278:29509-29514(2003).
RN   [5]
RP   FUNCTION.
RX   PubMed=15537867; DOI=10.1124/mol.104.007138;
RA   Chen Z.S., Guo Y., Belinsky M.G., Kotova E., Kruh G.D.;
RT   "Transport of bile acids, sulfated steroids, estradiol 17-beta-D-
RT   glucuronide, and leukotriene C4 by human multidrug resistance protein
RT   8 (ABCC11).";
RL   Mol. Pharmacol. 67:545-557(2005).
RN   [6]
RP   POLYMORPHISM, VARIANT ARG-180, CHARACTERIZATION OF VARIANT ARG-180,
RP   AND FUNCTION IN SECRETION OF EARWAX.
RX   PubMed=16444273; DOI=10.1038/ng1733;
RA   Yoshiura K., Kinoshita A., Ishida T., Ninokata A., Ishikawa T.,
RA   Kaname T., Bannai M., Tokunaga K., Sonoda S., Komaki R., Ihara M.,
RA   Saenko V.A., Alipov G.K., Sekine I., Komatsu K., Takahashi H.,
RA   Nakashima M., Sosonkina N., Mapendano C.K., Ghadami M., Nomura M.,
RA   Liang D.-S., Miwa N., Kim D.-K., Garidkhuu A., Natsume N., Ohta T.,
RA   Tomita H., Kaneko A., Kikuchi M., Russomando G., Hirayama K.,
RA   Ishibashi M., Takahashi A., Saitou N., Murray J.C., Saito S.,
RA   Nakamura Y., Niikawa N.;
RT   "A SNP in the ABCC11 gene is the determinant of human earwax type.";
RL   Nat. Genet. 38:324-330(2006).
RN   [7]
RP   VARIANT ARG-180, CHARACTERIZATION OF VARIANTS HIS-19; ARG-180;
RP   GLU-317; MET-546; TRP-630; ILE-648; ILE-687; ARG-735; VAL-970 AND
RP   ARG-1344, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   GLYCOSYLATION AT ASN-838 AND ASN-844, POLYMORPHISM, AND MUTAGENESIS OF
RP   GLY-180; ASN-838 AND ASN-844.
RX   PubMed=19383836; DOI=10.1096/fj.09-129098;
RA   Toyoda Y., Sakurai A., Mitani Y., Nakashima M., Yoshiura K.,
RA   Nakagawa H., Sakai Y., Ota I., Lezhava A., Hayashizaki Y., Niikawa N.,
RA   Ishikawa T.;
RT   "Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in
RT   the human ABC transporter ABCC11 gene determine earwax type?";
RL   FASEB J. 23:2001-2013(2009).
RN   [8]
RP   VARIANT ARG-180, CHARACTERIZATION OF VARIANT ARG-180, FUNCTION, TISSUE
RP   SPECIFICITY, AND POLYMORPHISM.
RX   PubMed=19710689; DOI=10.1038/jid.2009.254;
RA   Martin A., Saathoff M., Kuhn F., Max H., Terstegen L., Natsch A.;
RT   "A functional ABCC11 allele is essential in the biochemical formation
RT   of human axillary odor.";
RL   J. Invest. Dermatol. 130:529-540(2010).
RN   [9]
RP   CHARACTERIZATION OF VARIANTS HIS-19; ARG-180; GLU-317; MET-546;
RP   ILE-648 AND ARG-1344, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=25896536; DOI=10.1038/tpj.2015.27;
RA   Arlanov R., Lang T., Jedlitschky G., Schaeffeler E., Ishikawa T.,
RA   Schwab M., Nies A.T.;
RT   "Functional characterization of common protein variants in the efflux
RT   transporter ABCC11 and identification of T546M as functionally
RT   damaging variant.";
RL   Pharmacogenomics J. 16:193-201(2016).
CC   -!- FUNCTION: Participates in physiological processes involving bile
CC       acids, conjugated steroids and cyclic nucleotides
CC       (PubMed:12764137, PubMed:15537867). Enhances the cellular
CC       extrusion of cAMP and cGMP (PubMed:12764137, PubMed:15537867).
CC       Stimulates the ATP-dependent uptake of a range of physiological
CC       and synthetic lipophilic anions, including the glutathione S-
CC       conjugates leukotriene C4 and dinitrophenyl S-glutathione, steroid
CC       sulfates such as dehydroepiandrosterone 3-sulfate (DHEAS) and
CC       estrone 3-sulfate, glucuronides such as estradiol 17-beta-D-
CC       glucuronide (E(2)17betaG), the monoanionic bile acids glycocholate
CC       and taurocholate, and methotrexate (PubMed:15537867,
CC       PubMed:25896536). Probably functions to secrete earwax
CC       (PubMed:16444273, PubMed:19383836). Required for the secretion of
CC       components contributing to axillary odor formation
CC       (PubMed:19710689). {ECO:0000269|PubMed:12764137,
CC       ECO:0000269|PubMed:15537867, ECO:0000269|PubMed:16444273,
CC       ECO:0000269|PubMed:19383836, ECO:0000269|PubMed:19710689,
CC       ECO:0000269|PubMed:25896536}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19383836,
CC       ECO:0000269|PubMed:25896536}; Multi-pass membrane protein
CC       {ECO:0000255}. Vacuole membrane {ECO:0000269|PubMed:19383836}.
CC       Cytoplasmic vesicle membrane {ECO:0000269|PubMed:25896536}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96J66-1; Sequence=Displayed;
CC       Name=2; Synonyms=Isoform A;
CC         IsoId=Q96J66-2; Sequence=VSP_017351;
CC   -!- TISSUE SPECIFICITY: Expressed in ceruminous apocrine gland (at
CC       protein level) (PubMed:19383836, PubMed:19710689). Expressed in
CC       many tissues. Not expressed in kidney, spleen and colon. Highly
CC       expressed in breast cancer. Expressed at moderate levels in normal
CC       breast and testis and at very low levels in liver, brain and
CC       placenta. {ECO:0000269|PubMed:11483364,
CC       ECO:0000269|PubMed:11591886, ECO:0000269|PubMed:19383836,
CC       ECO:0000269|PubMed:19710689}.
CC   -!- POLYMORPHISM: Polymorphism in ABCC11 is associated with variation
CC       in apocrine gland secretion [MIM:117800]. This determines
CC       different ear wax phenotypes, presence or absence of axillary
CC       odor, and variation in colostrum secretion. Characteristic of
CC       earwax and strength of axillary odor are most likely
CC       interconnected. Human earwax is a Mendelian trait consisting of
CC       wet and dry types. The wet earwax is brownish and sticky, whereas
CC       the dry type lacks cerumen. The wet cerumen phenotype is
CC       completely dominant. The dry type is seen frequently (80-95%)
CC       among East Asians, but uncommon (0-3%) in populations of European
CC       and African origins. Intermediate frequencies (30-50%) of the dry
CC       type are seen in populations of Southern Asia, the Pacific
CC       Islands, Central Asia and Asia Minor, as well as among the Native
CC       North American and Inuit of Asian ancestry. The allele with Arg-
CC       180 is responsible for the dry earwax phenotype and lack of
CC       axillary odor. {ECO:0000269|PubMed:16444273,
CC       ECO:0000269|PubMed:19383836, ECO:0000269|PubMed:19710689}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Of earwax and migration
CC       - Issue 67 of February 2006;
CC       URL="http://web.expasy.org/spotlight/back_issues/067";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q96J66";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY040219; AAK76739.1; -; mRNA.
DR   EMBL; AF367202; AAK58869.1; -; mRNA.
DR   EMBL; AF411579; AAL99902.1; -; mRNA.
DR   EMBL; AF352582; AAK19755.1; -; mRNA.
DR   CCDS; CCDS10732.1; -. [Q96J66-1]
DR   CCDS; CCDS10733.1; -. [Q96J66-2]
DR   RefSeq; NP_115972.2; NM_032583.3. [Q96J66-1]
DR   RefSeq; NP_149163.2; NM_033151.3. [Q96J66-1]
DR   RefSeq; NP_660187.1; NM_145186.2. [Q96J66-2]
DR   RefSeq; XP_016879284.1; XM_017023795.1. [Q96J66-1]
DR   RefSeq; XP_016879285.1; XM_017023796.1. [Q96J66-1]
DR   RefSeq; XP_016879286.1; XM_017023797.1. [Q96J66-1]
DR   RefSeq; XP_016879287.1; XM_017023798.1. [Q96J66-1]
DR   RefSeq; XP_016879288.1; XM_017023799.1. [Q96J66-1]
DR   RefSeq; XP_016879289.1; XM_017023800.1. [Q96J66-1]
DR   UniGene; Hs.652267; -.
DR   ProteinModelPortal; Q96J66; -.
DR   SMR; Q96J66; -.
DR   STRING; 9606.ENSP00000349017; -.
DR   ChEMBL; CHEMBL2073702; -.
DR   DrugBank; DB00286; Conjugated Equine Estrogens.
DR   DrugBank; DB02527; Cyclic Adenosine Monophosphate.
DR   DrugBank; DB00158; Folic Acid.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB04348; Taurocholic Acid.
DR   TCDB; 3.A.1.208.13; the atp-binding cassette (abc) superfamily.
DR   iPTMnet; Q96J66; -.
DR   PhosphoSitePlus; Q96J66; -.
DR   BioMuta; ABCC11; -.
DR   DMDM; 74762666; -.
DR   MaxQB; Q96J66; -.
DR   PaxDb; Q96J66; -.
DR   PeptideAtlas; Q96J66; -.
DR   PRIDE; Q96J66; -.
DR   DNASU; 85320; -.
DR   Ensembl; ENST00000353782; ENSP00000311326; ENSG00000121270. [Q96J66-2]
DR   Ensembl; ENST00000356608; ENSP00000349017; ENSG00000121270. [Q96J66-1]
DR   Ensembl; ENST00000394747; ENSP00000378230; ENSG00000121270. [Q96J66-1]
DR   Ensembl; ENST00000394748; ENSP00000378231; ENSG00000121270. [Q96J66-1]
DR   GeneID; 85320; -.
DR   KEGG; hsa:85320; -.
DR   UCSC; uc002eff.1; human. [Q96J66-1]
DR   CTD; 85320; -.
DR   DisGeNET; 85320; -.
DR   GeneCards; ABCC11; -.
DR   HGNC; HGNC:14639; ABCC11.
DR   HPA; CAB032513; -.
DR   HPA; HPA031980; -.
DR   HPA; HPA031981; -.
DR   HPA; HPA031982; -.
DR   MIM; 117800; phenotype.
DR   MIM; 607040; gene.
DR   neXtProt; NX_Q96J66; -.
DR   OpenTargets; ENSG00000121270; -.
DR   PharmGKB; PA24393; -.
DR   eggNOG; KOG0054; Eukaryota.
DR   eggNOG; COG1132; LUCA.
DR   GeneTree; ENSGT00870000136442; -.
DR   HOVERGEN; HBG108314; -.
DR   InParanoid; Q96J66; -.
DR   KO; K05671; -.
DR   OMA; SFWWLSY; -.
DR   OrthoDB; EOG091G01TC; -.
DR   PhylomeDB; Q96J66; -.
DR   TreeFam; TF352085; -.
DR   Reactome; R-HSA-382556; ABC-family proteins mediated transport.
DR   GeneWiki; ABCC11; -.
DR   GenomeRNAi; 85320; -.
DR   PRO; PR:Q96J66; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000121270; -.
DR   CleanEx; HS_ABCC11; -.
DR   ExpressionAtlas; Q96J66; baseline and differential.
DR   Genevisible; Q96J66; HS.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005774; C:vacuolar membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:GO_Central.
DR   GO; GO:0043225; F:ATPase-coupled anion transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0008514; F:organic anion transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015216; F:purine nucleotide transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015711; P:organic anion transport; IDA:UniProtKB.
DR   GO; GO:0015865; P:purine nucleotide transport; IDA:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR030251; ABCC11.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR24223:SF308; PTHR24223:SF308; 1.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Cytoplasmic vesicle; Glycoprotein; Membrane; Nucleotide-binding;
KW   Polymorphism; Reference proteome; Repeat; Transmembrane;
KW   Transmembrane helix; Transport; Vacuole.
FT   CHAIN         1   1382       ATP-binding cassette sub-family C member
FT                                11.
FT                                /FTId=PRO_0000225594.
FT   TOPO_DOM      1    163       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    164    184       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    195    215       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    271    291       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    297    317       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    384    404       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    418    438       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    439    806       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    807    827       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    864    884       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    931    951       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM   1050   1070       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1071   1382       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      163    443       ABC transmembrane type-1 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN      508    732       ABC transporter 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   DOMAIN      806   1105       ABC transmembrane type-1 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN     1141   1375       ABC transporter 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND     544    551       ATP 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND    1175   1182       ATP 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   CARBOHYD    838    838       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255,
FT                                ECO:0000269|PubMed:19383836}.
FT   CARBOHYD    844    844       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255,
FT                                ECO:0000269|PubMed:19383836}.
FT   CARBOHYD    992    992       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ    1261   1298       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11688999}.
FT                                /FTId=VSP_017351.
FT   VARIANT      19     19       R -> H (no effect on glycosylation; no
FT                                effect on transport activity; no effect
FT                                on plasma membrane localization;
FT                                dbSNP:rs16945988).
FT                                {ECO:0000269|PubMed:19383836,
FT                                ECO:0000269|PubMed:25896536}.
FT                                /FTId=VAR_025437.
FT   VARIANT     180    180       G -> R (in dry earwax and lack of
FT                                axillary odor phenotype; loss of N-
FT                                glycosylation; strongly reduced plasma
FT                                membrane localization; reduced transport
FT                                activity; decreased protein concentration
FT                                in axillary sweat; dbSNP:rs17822931).
FT                                {ECO:0000269|PubMed:16444273,
FT                                ECO:0000269|PubMed:19383836,
FT                                ECO:0000269|PubMed:19710689,
FT                                ECO:0000269|PubMed:25896536}.
FT                                /FTId=VAR_025438.
FT   VARIANT     317    317       A -> E (no effect on glycoslylation; no
FT                                effect on transport activity; no effect
FT                                on plasma membrane localization;
FT                                dbSNP:rs11863236).
FT                                {ECO:0000269|PubMed:11591886,
FT                                ECO:0000269|PubMed:19383836,
FT                                ECO:0000269|PubMed:25896536}.
FT                                /FTId=VAR_048144.
FT   VARIANT     546    546       T -> M (reduced transport activity; no
FT                                effect on glycoslylation; no effect on
FT                                plasma membrane localization;
FT                                dbSNP:rs17822471).
FT                                {ECO:0000269|PubMed:19383836,
FT                                ECO:0000269|PubMed:25896536}.
FT                                /FTId=VAR_048145.
FT   VARIANT     630    630       R -> W (no effect on glycoslylation;
FT                                dbSNP:rs41282045).
FT                                {ECO:0000269|PubMed:19383836}.
FT                                /FTId=VAR_077575.
FT   VARIANT     648    648       V -> I (no effect on glycoslylation; no
FT                                effect on transport activity; no effect
FT                                on plasma membrane localization;
FT                                dbSNP:rs16945930).
FT                                {ECO:0000269|PubMed:19383836,
FT                                ECO:0000269|PubMed:25896536}.
FT                                /FTId=VAR_048146.
FT   VARIANT     687    687       V -> I (no effect on glycoslylation;
FT                                dbSNP:rs16945928).
FT                                {ECO:0000269|PubMed:19383836}.
FT                                /FTId=VAR_048147.
FT   VARIANT     735    735       K -> R (no effect on glycoslylation;
FT                                dbSNP:rs16945926).
FT                                {ECO:0000269|PubMed:19383836}.
FT                                /FTId=VAR_048148.
FT   VARIANT     970    970       M -> V (no effect on glycoslylation;
FT                                dbSNP:rs41280943).
FT                                {ECO:0000269|PubMed:19383836}.
FT                                /FTId=VAR_077576.
FT   VARIANT    1344   1344       H -> R (no effect on glycoslylation; no
FT                                effect on transport activity; no effect
FT                                on plasma membrane localization;
FT                                dbSNP:rs16945916).
FT                                {ECO:0000269|PubMed:11591886,
FT                                ECO:0000269|PubMed:19383836,
FT                                ECO:0000269|PubMed:25896536}.
FT                                /FTId=VAR_048149.
FT   MUTAGEN     180    180       G->A,P: Does not affect N-glycosylation.
FT                                {ECO:0000269|PubMed:19383836}.
FT   MUTAGEN     180    180       G->L,H,D,E: Loss of N-glycosylation.
FT                                {ECO:0000269|PubMed:19383836}.
FT   MUTAGEN     838    838       N->Q: Loss of N-glycosylation.
FT                                {ECO:0000269|PubMed:19383836}.
FT   MUTAGEN     844    844       N->Q: Loss of N-glycosylation.
FT                                {ECO:0000269|PubMed:19383836}.
FT   CONFLICT    199    199       V -> A (in Ref. 2; AAK58869/AAL99902).
FT                                {ECO:0000305}.
FT   CONFLICT    311    311       L -> P (in Ref. 3; AAK19755).
FT                                {ECO:0000305}.
FT   CONFLICT    363    363       K -> E (in Ref. 2; AAK58869/AAL99902).
FT                                {ECO:0000305}.
FT   CONFLICT    395    395       T -> A (in Ref. 3; AAK19755).
FT                                {ECO:0000305}.
FT   CONFLICT    632    632       L -> P (in Ref. 3; AAK19755).
FT                                {ECO:0000305}.
FT   CONFLICT    688    688       L -> Q (in Ref. 3; AAK19755).
FT                                {ECO:0000305}.
FT   CONFLICT    702    702       I -> V (in Ref. 3; AAK19755).
FT                                {ECO:0000305}.
FT   CONFLICT    982    982       K -> E (in Ref. 3; AAK19755).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1382 AA;  154301 MW;  0F3C17DC69AE97F4 CRC64;
     MTRKRTYWVP NSSGGLVNRG IDIGDDMVSG LIYKTYTLQD GPWSQQERNP EAPGRAAVPP
     WGKYDAALRT MIPFRPKPRF PAPQPLDNAG LFSYLTVSWL TPLMIQSLRS RLDENTIPPL
     SVHDASDKNV QRLHRLWEEE VSRRGIEKAS VLLVMLRFQR TRLIFDALLG ICFCIASVLG
     PILIIPKILE YSEEQLGNVV HGVGLCFALF LSECVKSLSF SSSWIINQRT AIRFRAAVSS
     FAFEKLIQFK SVIHITSGEA ISFFTGDVNY LFEGVCYGPL VLITCASLVI CSISSYFIIG
     YTAFIAILCY LLVFPLAVFM TRMAVKAQHH TSEVSDQRIR VTSEVLTCIK LIKMYTWEKP
     FAKIIEDLRR KERKLLEKCG LVQSLTSITL FIIPTVATAV WVLIHTSLKL KLTASMAFSM
     LASLNLLRLS VFFVPIAVKG LTNSKSAVMR FKKFFLQESP VFYVQTLQDP SKALVFEEAT
     LSWQQTCPGI VNGALELERN GHASEGMTRP RDALGPEEEG NSLGPELHKI NLVVSKGMML
     GVCGNTGSGK SSLLSAILEE MHLLEGSVGV QGSLAYVPQQ AWIVSGNIRE NILMGGAYDK
     ARYLQVLHCC SLNRDLELLP FGDMTEIGER GLNLSGGQKQ RISLARAVYS DRQIYLLDDP
     LSAVDAHVGK HIFEECIKKT LRGKTVVLVT HQLQYLEFCG QIILLENGKI CENGTHSELM
     QKKGKYAQLI QKMHKEATSD MLQDTAKIAE KPKVESQALA TSLEESLNGN AVPEHQLTQE
     EEMEEGSLSW RVYHHYIQAA GGYMVSCIIF FFVVLIVFLT IFSFWWLSYW LEQGSGTNSS
     RESNGTMADL GNIADNPQLS FYQLVYGLNA LLLICVGVCS SGIFTKVTRK ASTALHNKLF
     NKVFRCPMSF FDTIPIGRLL NCFAGDLEQL DQLLPIFSEQ FLVLSLMVIA VLLIVSVLSP
     YILLMGAIIM VICFIYYMMF KKAIGVFKRL ENYSRSPLFS HILNSLQGLS SIHVYGKTED
     FISQFKRLTD AQNNYLLLFL SSTRWMALRL EIMTNLVTLA VALFVAFGIS STPYSFKVMA
     VNIVLQLASS FQATARIGLE TEAQFTAVER ILQYMKMCVS EAPLHMEGTS CPQGWPQHGE
     IIFQDYHMKY RDNTPTVLHG INLTIRGHEV VGIVGRTGSG KSSLGMALFR LVEPMAGRIL
     IDGVDICSIG LEDLRSKLSV IPQDPVLLSG TIRFNLDPFD RHTDQQIWDA LERTFLTKAI
     SKFPKKLHTD VVENGGNFSV GERQLLCIAR AVLRNSKIIL IDEATASIDM ETDTLIQRTI
     REAFQGCTVL VIAHRVTTVL NCDHILVMGN GKVVEFDRPE VLRKKPGSLF AALMATATSS
     LR
//
